INDV Indivior Plc

$INDV Does Indivior's $95M sale of its SUBUTEX tablet business in France and Germany matter with the Supernus merger days away? 🤝 Indivior, which makes the opioid-addiction injection SUBLOCADE and whose October 29 Q3 release showed revenue up 13% to $356M, says in its 10-Q that on October 19, 2026 it agreed to sell its SUBUTEX tablet business in France and Germany for $95M ⚠️ Against that, the filing gives no profit or gain figure for the business, so the deal's effect on earnings cannot be worked out, though the business made less than 4% of 2025 net revenue and Indivior expects a smaller share in 2026 📅 Next: Indivior expects the Supernus merger to close on or about November 2, 2026, and the SUBUTEX sale to close later in 2026, with 10% of the price due only after regulatory approval expected in the first half of 2027 Source: SEC 10-Q, Oct 29 + Q3 release (8-K), Oct 29

$INDV Can Indivior's 76% EBITDA jump to $211M, built partly on spending cuts, carry into the Supernus merger? 🏢 Indivior, which makes SUBLOCADE, a long-acting injection for opioid addiction, was worth about $4.10B at $34.77 at 16:00 ET on October 28, 2026, and its third-quarter net income more than tripled to $137M, or $1.12 per diluted share, against $42M in the same 2025 quarter 💰 On the other side, operating cash flow for the nine months rose to $317M from $194M and paid for $302M of buybacks, which cut the diluted share count to 122M from 129M 📅 Next: The merger is expected to close on November 2, 2026, and the combined Supernus, Inc. trades as SUPN beginning November 3, 2026 Source: GlobeNewswire release + SEC 8-K, Oct 29

$INDV reported earnings before the open: adjusted EPS of $1.32 vs. $1.06 estimated, a beat of 24.5%. I used Stock Meadow to review the results.

$INDV Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $1.32 up 83.33% YoY • Reported revenue of $356M up 13.38% YoY • Indivior is on track to achieve FY 2026 standalone guidance before merger closing: net revenue $1.3B to $1.37B, total SUBLOCADE net revenue $1.01B to $1.05B, and adjusted EBITDA $700M to $740M.

$INDV reports earnings tomorrow before the open. I’m bullish heading into the report: INDV has beaten EPS estimates in 7 of its last 8 reports, according to Stock Meadow.

Latest company news, October 19, 2026: Indivior will report Q3 results on October 29 at 7:00 a.m. ET. Shareholders of Indivior and Supernus approved the merger on October 15; closing is expected November 2, per company statements. Indivior $INDV: SUBLOCADE, Supernus Merger And Dividend Deeper dive in our hub. Not investment advice.